In the study, patients were randomized to either tirzepatide 5 mg, 10 mg, or 15 mg vs semaglutide 1 mg. The mean age was 56.6 years, 53% were women, mean A1c was 8.3%, and mean BMI was 34.2.

The phase 3b open-label, randomized controlled trial showed that patients treated with tirzepatide vs semaglutide lost an average of 20.2% vs 13.7% of their baseline weight over the 72 weeks.

There were 7,881 adults included in the study (mean age, 51.3 years; 75.2% women), of whom 6,109 were prescribed semaglutide and 1,772 were prescribed tirzepatide.

To assess the efficacy of tirzepatide compared with semaglutide in achieving standard and intensive cardiometabolic targets among adults with T2D, researchers conducted a post hoc analysis of the ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

Unlike semaglutide or liraglutide that only activate the GLP-1 receptor, the dual agonist tirzepatide works on the GLP-1 and GIP receptors, two important hormone pathways that help control hunger.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or ...

Neurodegeneration and stroke After semaglutide and tirzepatide in patients with diabetes and obesity. JAMA Netw Open. 2025;8 (7):e2521016. doi:10.1001/jamanetworkopen.2025.21016 2.

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with obstructive sleep apnea and type 2 diabetes, according to data ...

Research Summary Tirzepatide vs. Semaglutide Once Weekly in Patients with Type 2 Diabetes August 4, 2021 DOI: 10.1056/NEJMdo006114 Save ...

Quick Take Tirzepatide vs. Semaglutide for Obesity July 2, 2025 DOI: 10.1056/NEJMdo008040 Save ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.